JP2000503534A5 - - Google Patents

Download PDF

Info

Publication number
JP2000503534A5
JP2000503534A5 JP1997525405A JP52540597A JP2000503534A5 JP 2000503534 A5 JP2000503534 A5 JP 2000503534A5 JP 1997525405 A JP1997525405 A JP 1997525405A JP 52540597 A JP52540597 A JP 52540597A JP 2000503534 A5 JP2000503534 A5 JP 2000503534A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997525405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000503534A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/000370 external-priority patent/WO1997025446A1/en
Publication of JP2000503534A publication Critical patent/JP2000503534A/ja
Publication of JP2000503534A5 publication Critical patent/JP2000503534A5/ja
Ceased legal-status Critical Current

Links

JP9525405A 1996-01-05 1997-01-03 アデノウイルスベクターのリコンビナーゼ媒介生成 Ceased JP2000503534A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58370396A 1996-01-05 1996-01-05
US08/583,703 1996-01-05
PCT/US1997/000370 WO1997025446A1 (en) 1996-01-05 1997-01-03 Recombinase-mediated generation of adenoviral vectors

Publications (2)

Publication Number Publication Date
JP2000503534A JP2000503534A (ja) 2000-03-28
JP2000503534A5 true JP2000503534A5 (en:Method) 2004-11-11

Family

ID=24334219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9525405A Ceased JP2000503534A (ja) 1996-01-05 1997-01-03 アデノウイルスベクターのリコンビナーゼ媒介生成

Country Status (7)

Country Link
US (1) US6156497A (en:Method)
EP (1) EP0927263A1 (en:Method)
JP (1) JP2000503534A (en:Method)
AU (1) AU1695197A (en:Method)
CA (1) CA2239366A1 (en:Method)
NZ (1) NZ330553A (en:Method)
WO (1) WO1997025446A1 (en:Method)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730507B1 (en) 1993-06-24 2004-05-04 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US6756226B2 (en) * 1994-05-31 2004-06-29 Frank L. Graham Enhanced system for construction of adenovirus vectors
US6379943B1 (en) * 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US6964861B1 (en) 1998-11-13 2005-11-15 Invitrogen Corporation Enhanced in vitro recombinational cloning of using ribosomal proteins
US6974694B2 (en) 1995-06-07 2005-12-13 Advec, Inc. Adenoviruses for control of gene expression
ATE222289T1 (de) 1995-06-07 2002-08-15 Invitrogen Corp Rekombinatorische klonierung in vitro unter verwendung genmanipulierter rekombinationsorte
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
FR2749857B1 (fr) * 1996-06-12 1998-08-14 Centre Nat Rech Scient Generation de molecules replicatives in vivo
CA2272121A1 (en) * 1996-11-19 1998-05-28 Uab Research Foundation Chimeric retrovirus/adenovirus system
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US7030096B1 (en) * 1997-02-13 2006-04-18 Albert Einstein College Of Medicine Of Yeshiva University Method of enhancing relaxation of penile smooth muscle by introduction of DNA encoding maxi-K potassium channel protein
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
WO1998042856A1 (en) 1997-03-21 1998-10-01 Enzo Therapeutics, Inc., A Fully Owned Subsidiary Of Enzo Biochem, Inc. Vectors and viral vectors, and packaging cell lines for propagating same
WO1998046778A1 (en) * 1997-04-11 1998-10-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Transgenomic viruses and the use thereof
ATE303448T1 (de) 1997-09-23 2005-09-15 Genvec Inc Duale selektionkassette und sie enthaltende plasmide
DE69836092T2 (de) 1997-10-24 2007-05-10 Invitrogen Corp., Carlsbad Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
US7351578B2 (en) 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
DE19807265C2 (de) * 1998-02-20 2000-01-05 Centeon Pharma Gmbh Adenoviraler Transfervektor für den Gentransport einer DNA-Sequenz
US6413776B1 (en) * 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US6576463B1 (en) 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
EP2336148A1 (en) 1999-03-02 2011-06-22 Life Technologies Corporation Compositions and methods for use in recombinational cloning of nucleic acids
CA2366914C (en) * 1999-03-05 2010-05-11 Merck & Co., Inc. Enhanced system for construction of adenovirus vectors
NZ530816A (en) * 1999-12-10 2005-10-28 Invitrogen Corp Use of multiple recombination sites with unique specificity in recombinational cloning
US7052904B2 (en) 2000-01-31 2006-05-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hybrid adeno-retroviral vector for the transfection of cells
US7244560B2 (en) 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP2336339A3 (en) * 2000-09-25 2011-09-14 The Regents of the University of Michigan Production of viral vectors
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
US7226779B2 (en) 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
WO2002092786A2 (en) * 2001-03-26 2002-11-21 The Board Of Trustees Of The Leland Stanford Junior University A helper dependent adenoviral vector system and methods for using the same
WO2002085287A2 (en) * 2001-04-18 2002-10-31 Genstar Therapeutics Corp. Minimal adenoviral vectors for immunization
EP1516055A4 (en) * 2002-01-24 2007-08-08 Scripps Research Inst FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS
US8304233B2 (en) 2002-06-04 2012-11-06 Poetic Genetics, Llc Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
US20040203133A1 (en) * 2003-01-07 2004-10-14 Anja Ehrhardt Helper dependent adenoviral vector system and methods for using the same
CA2522786A1 (en) * 2003-03-19 2004-09-30 Isogenis, Inc. Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain
EP1613757A2 (en) 2003-03-28 2006-01-11 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
DE602004027538D1 (de) 2003-12-01 2010-07-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
WO2006012416A2 (en) 2004-07-20 2006-02-02 Isogenis, Inc. Specific inhibition of autoimmunity and diseases associated with autoantigens
PL1804835T3 (pl) 2004-09-13 2010-11-30 Genzyme Corp Konstrukty multimeryczne
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
SI1988823T1 (sl) 2006-02-09 2018-12-31 Genzyme Corporation Počasna intraventrikularna dostava
WO2010033722A2 (en) 2008-09-17 2010-03-25 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
US20230172175A1 (en) 2020-03-15 2023-06-08 Proteinea, Inc. Recombinant protein production in insects

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293460C (en) * 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
WO1994023582A1 (en) * 1993-04-08 1994-10-27 Genetic Therapy, Inc. Adenoviral vectors including dna encoding lung surfactant protein
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
DE69535178T2 (de) * 1994-06-10 2006-12-14 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
US5650309A (en) * 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors

Similar Documents

Publication Publication Date Title
JP2000502280A5 (en:Method)
JP2000501771A5 (en:Method)
JP2000501599A5 (en:Method)
JP2000501018A5 (en:Method)
JP2000500076A5 (en:Method)
JP2000506880A5 (en:Method)
JP2000501324A5 (en:Method)
JP2000500026A5 (en:Method)
JP2000502472A5 (en:Method)
JP2000501825A5 (en:Method)
JP2000501338A5 (en:Method)
JP2000500874A5 (en:Method)
JP2000502485A5 (en:Method)
JP2000502425A5 (en:Method)
JP2000502568A5 (en:Method)
JP2000501774A5 (en:Method)
JP2000500912A5 (en:Method)
JP2000502570A5 (en:Method)
JP2000501876A5 (en:Method)
JP2000501744A5 (en:Method)
JP2000501229A5 (en:Method)
JP2000502316A5 (en:Method)
JP2000500857A5 (en:Method)
JP2000502714A5 (en:Method)
JP2000501569A5 (en:Method)